| Similar Articles |
 |
The Motley Fool July 6, 2004 Alyce Lomax |
Not Ready for Rite Aid Can the drugstore chain hold a candle to the competition? Its shares are trading at 22 times forward earnings, making it a seemingly less-than-advantageous time to place a bet on them.  |
The Motley Fool January 4, 2005 Seth Jayson |
Rite Aid Still Needs First Aid Sales keep slacking for this tough turnaround. This doesn't mean investors should necessarily jump ship.  |
The Motley Fool June 11, 2007 Mike Cianciolo |
Rite Aid's Generic Sales The drugstore chain gradually increases sales, and catches up to the big boys in one way. Investors, take note.  |
The Motley Fool January 4, 2008 Timothy M. Otte |
Drugstore Sales Droop in December The three major drugstore chains, Walgreen, CVS, and Rite Aid, all report soft sales for December.  |
The Motley Fool March 9, 2004 Alyce Lomax |
February Frenzy at CVS, Rite Aid The flu season's early end hasn't stopped drugstore retailers.  |
The Motley Fool September 24, 2004 Seth Jayson |
Kick This Drug Habit Rite Aid offers slow sales and minuscule shareholder rewards.  |
The Motley Fool July 7, 2004 Steven Mallas |
CVS's Bright Picture Send CVS your digital photos over the Net, pick them up the next day. While competitors are sure to follow suit, this still shows how intellegent and creative this drugstore blue chip can be.  |
The Motley Fool June 10, 2004 Alyce Lomax |
Summer Starts at CVS The drugstore company releases same-store sales results on the cusp of its Eckerd acquisition.  |
The Motley Fool March 22, 2004 Alyce Lomax |
Walgreen's Green Quarter Investors take an earnings miss to heart. But the future looks good.  |
The Motley Fool July 6, 2004 Steven Mallas |
Walgreen's Sunny Sales The retail pharmacy has a resplendently ruddy June, with comp sales increasing more than 10%.  |
The Motley Fool April 8, 2004 Seth Jayson |
Rite Aid Wrings Out Profits Net store closings and comps increases bring black ink to the pharmacy's bottom line.  |
The Motley Fool April 9, 2007 Mike Cianciolo |
CVS: Continued Vigorous Sales The drugstore chain grows sales and itself in March. Investors, take note.  |
The Motley Fool June 25, 2004 Steven Mallas |
Rite Aid in the Shadows The first quarter for Rite Aid, the pharmaceutical retailer, shows a profit, but is it time to add this stock to your portfolio?  |
The Motley Fool December 11, 2006 Matthew Crews |
Rite Aid: Comps Mean Competition The pharmacy chain reported positive same-store results for November. Investors, take note.  |
The Motley Fool June 21, 2004 Seth Jayson |
Walgreen's Fine Follow-Up It's another solid quarter for America's soon-to-be No. 2 drugstore.  |
The Motley Fool February 4, 2005 Steven Mallas |
Walgreen's Wonderful Comps This drugstore chain doesn't need any medical attention. January comps prove it.  |
The Motley Fool September 27, 2007 Ryan Fuhrmann |
Rite Aid Looks a Little Peaked Bigger doesn't necessarily mean better for the drugstore retailer; it has quite a bit of work to do to convince investors it can successfully manage the empire that it has acquired.  |
The Motley Fool January 5, 2007 Matthew Crews |
Rite Aid's Baby Steps If Rite Aid does manage 5% operating margins, this pharmacy chain's shares will get the love they deserve.  |
The Motley Fool March 8, 2005 Seth Jayson |
Rite Aid Wretched? Value investors may be interested in Rite Aid.  |
The Motley Fool June 2, 2004 Alyce Lomax |
Walgreen's Mellow May Will the drugstore chain get a taste of its own medicine?  |
The Motley Fool January 5, 2004 Jeff Hwang |
Prescriptions Boost Walgreen Earnings and sales bumped by early flu season and improved non-pharmacy sales.  |
The Motley Fool December 23, 2003 Dave Marino-Nachison |
Duane Reade's NY Story The well-known New York drugstore chain is going private after just under six years.  |
The Motley Fool April 11, 2008 Ryan Fuhrmann |
Rite Aid Hasn't Fully Recovered Rite Aid needs to be nursed back to health after its acquisition of Brooks Eckerd.  |
The Motley Fool March 24, 2004 Dave Marino-Nachison |
Eking Out an Eckerd Deal Investors are still waiting for a new leader to be crowned in the U.S. drugstore business.  |
The Motley Fool August 4, 2004 Phil Wohl |
CVS's Prescription for Competition The national drugstore chain is looking to take advantage of increased size.  |
The Motley Fool April 13, 2007 Ryan Fuhrmann |
Rite Aid's Right-Size Ambitions If the retail pharmacy chain can improve its net margins, reduce debt, and smoothly integrate its latest acquisition, the stock's upside would be substantial.  |
The Motley Fool September 25, 2009 Chris Jones |
The First Symptom of Health-Care Troubles? Rite Aid's problems imply bad news for consumers and the health-care system.  |
The Motley Fool September 14, 2006 Ryan Fuhrmann |
Playing Defense With the Drugstore Industry Retail pharmacy August sales trends help investors discern the leader in this appealing sector.  |
The Motley Fool July 5, 2005 Alyce Lomax |
Business As Usual at Walgreen Walgreen's same-store sales for June certainly don't disappoint. Investors might question whether the retail pharmacy can keep up the great work.  |
The Motley Fool August 19, 2011 Ilan Moscovitz |
Rite Aid Is Cheaper Than You Think Rite Aid tends to generate much more free cash flow than net income, suggesting that -- while things may not exactly be going swimmingly -- the company's stock might be a bit cheaper than many investors realize.  |
The Motley Fool January 3, 2005 Nathan Slaughter |
Walgreen Seeing Green Rivals CVS and Rite Aid have a bitter pill to swallow as Walgreen stays strong. While Walgreen's revenues were in line with forecasts, the stronger-than-expected bottom line has the stock gaining ground.  |
The Motley Fool July 6, 2007 Timothy M. Otte |
Drugstore Sales Remain Healthy The big four drugstore chains report higher comparable sales in June. Walgreen... CVS... Rite Aid... Long's...  |
The Motley Fool October 4, 2005 Seth Jayson |
Same Old Same-Store Story Reports from Walgreen and Rite Aid confirm the obvious. Investors will nearly always do better buying the best company in any given space.  |
The Motley Fool May 9, 2005 Timothy M. Otte |
Flu Means All's Well for CVS Strong comp sales and benefits from the Eckerd acquisition drive CVS to a solid first quarter. Investors, take note.  |
The Motley Fool September 27, 2004 Phil Wohl |
Walgreen: Prescription for Success The leading drugstore retailer is leveraging prescription sales to produce record results. Fourth-quarter earnings grew to $0.32 per share, which was an 18% improvement over last year's $0.27.  |
The Motley Fool June 29, 2007 Ryan Fuhrmann |
Rite Aid's Recent Remedy Will increased market clout lead the drugstore operator to new highs? Investors, take note.  |
The Motley Fool March 28, 2005 Alyce Lomax |
A Cool Quarter for Walgreen Are second-quarter earnings putting a damper on Walgreen?  |
The Motley Fool September 29, 2011 Navjot Kaur |
Should You Write Off Rite Aid? Rite Aid posts a relatively better quarter as wellness rewards the company.  |
The Motley Fool December 16, 2004 Nathan Slaughter |
Rx: Get Some Earnings Quick The No. 3 drug chain Rite Aid posts a sharp drop in earnings and slashes guidance again.  |
The Motley Fool September 22, 2006 Ryan Fuhrmann |
More in Store at Rite Aid? The retail pharmacy posted strong second-quarter sales, and an acquisition could help long-term results. Investors, take note.  |
The Motley Fool September 22, 2005 Stephen D. Simpson |
Rite Aid Not Right Yet The bleeding seems to have stopped at this pharmacy, but recovery could be a long and slow road. Intrepid, not to mention patient, investors may see potential here, but there are far better turnaround ideas to be had.  |
The Motley Fool December 26, 2006 Matthew Crews |
Walgreen Represents This drugstore business has proven itself; does its stock match up?  |
The Motley Fool June 27, 2011 Shubh Datta |
All Is Not Yet Right at Rite Aid Drug retailer Rite Aid posts losses in its first fiscal quarter and sees further losses ahead.  |
The Motley Fool June 25, 2007 Ryan Fuhrmann |
Foolish Forecast: Rite Aid Aims for Healthy Growth The drugstore operator is set to report its first-quarter earnings. Investors, here is what you can expect to see.  |
The Motley Fool January 3, 2012 Shubh Datta |
Bright Spots for Rite Aid Better same-store sales help Rite Aid trim losses.  |
The Motley Fool February 12, 2004 Dave Marino-Nachison |
CVS Bags Big 2003 A strong year for the drugstore giant has spilled into January.  |
The Motley Fool September 26, 2007 Ryan Fuhrmann |
Foolish Forecast: Does Rite Aid Have the Right Rx? The retail pharmacy is set to release it second-quarter financial results. Investors, here is what you can expect to see.  |
The Motley Fool August 15, 2005 Bobby Shethia |
Walgreen's Prescription for Success The drugstore chain's smart and steady growth makes it a good choice for investors.  |
The Motley Fool April 4, 2007 Timothy M. Otte |
Walgreen's Comp Machine The drugstore operator steams through March with 8% comparable sales growth. The stock trades at a P/E of 24 times trailing-12-month earnings, about one-third higher than the average of all S&P 500 companies.  |
The Motley Fool January 7, 2010 Gerard Torres |
Walgreen Lives to Fight Another Day Despite recent success, Walgreen continues to face stiff competition.  |